Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAntonio Rueda‐DomínguezAPAntonio PintoASAlan P Skarbnik

Discussion

Loading...

Member takes

Overview

Observational analysis shows high safety and efficacy in relapsed large B-cell lymphoma, suggesting a promising treatment option.

Key Points

  • Efficacy of Glofitamab and polatuzumab vedotin demonstrated an overall response rate of 80.6%.
  • Complete response rate reached 62.0% in patients with relapsed large B-cell lymphoma.
  • Phase Ib/II study assessed treatment in patients having received prior therapies, indicating durable outcomes.
  • High efficacy and manageable safety suggest potential of this combination therapy in a challenging patient population.

Cite This Study

Rueda‐Domínguez et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d516https://doi.org/10.1182/blood-2025-5510
View Full Paper
Ask AI
Bookmark
Share